Drug Profile


Alternative Names: DT-009; DTI 0009; RG 14202

Latest Information Update: 18 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aderis Pharmaceuticals (CEASED)
  • Class Antiarrhythmics
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Supraventricular arrhythmias

Most Recent Events

  • 01 Jun 2005 As a result of corporate merger activities Aderis Pharmaceuticals has ceased operations
  • 22 Mar 2005 Data presented at the 106th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2005) have been added to the Arrhythmias pharmacodynamics section
  • 30 Jul 2004 Fujisawa has terminated its licence for selodenoson in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top